Liddle's syndrome caused by a novel missense mutation (P617L) of the epithelial sodium channel b subunit Methods Genetic analysis was performed in the proband, his relatives, and 100 control subjects. To determine the functional role of the mutation identified in the proband, we expressed the mutant or wild-type epithelial sodium channel in Xenopus laevis oocytes.
Results A novel point mutation, causing an expected substitution of a leucine residue for the second proline residue of the conserved PY motif (PPP T Y) of the b subunit was identified in the proband. The functional expression of the mutant epithelial sodium channel in X. laevis oocytes showed a three-fold increase in the amiloride-sensitive current as compared with that of the wild-type channel.
Conclusion This newly identified mutation adds to other missense mutations of the PY motif of the b subunit of the epithelial sodium channel, thus confirming its crucial role in the regulation of the epithelial sodium channel. To our knowledge, this is the first report of Liddle's syndrome in the Italian population, confirmed by genetic and functional analysis, with the identification of a gain-of-function mutation not previously reported. 
Introduction
Basic features of Liddle's syndrome include an autosomaldominant pattern of inheritance, early onset of saltsensitive hypertension, hypokalemia, inappropriate K þ excretion, metabolic alkalosis, and suppression of both plasma renin activity and aldosterone secretion. Moreover, the syndrome can be corrected by the epithelial Na þ channel blockers, amiloride or triamterene, together with reduced salt intake, but not by mineralocorticoidreceptor inhibitors [1, 2] . Furthermore, in those Liddle's syndrome patients who develop end-stage renal failure from nephrosclerosis, kidney transplantation normalizes serum potassium and attenuates the degree of hypertension [2] .
The mutations so far identified in Liddle's syndrome cause constitutive activation of the epithelial sodium channel (ENaC) [3] , which is mainly expressed in the aldosterone-sensitive distal nephron. This channel is composed of three homologous subunits, a, b and g. Each subunit consists of two transmembrane domains, a large extracellular loop, and short cytoplasmic amino and carboxyl termini [4] [5] [6] . Most identified mutations causing Liddle's syndrome delete a conserved proline-rich PY motif (PPP Â Y) in the cytoplasmic C-terminus region of the b [7] [8] [9] [10] [11] [12] [13] [14] or g subunits [15] [16] [17] of EnaC, or alter the same PY motif in the C-terminus of the b subunit [16, [18] [19] [20] [21] [22] [23] [24] [25] [26] , resulting in increased ENaC activity.
There are no previous reports on molecularly established cases of Liddle's syndrome in the Italian population. We report here a novel gain-of-function mutation, bENaC P617L, causing Liddle's syndrome in an Italian family. 2 ). The previous therapy was changed to amlodipine 5 mg/day and KCl oral supplements (40 mmol/day). Six weeks later, his PRA was 0.1 ng/ml/h and plasma aldosterone less than 1.0 ng/dl, despite an apparently normalized serum K þ (Table 1) .
Methods

Clinical findings in the proband
Glucocorticoid-remediable aldosteronism was excluded, based on both a low level of plasma aldosterone and a genetic test for the CYP11B1/CYP11B2 hybrid gene. Apparent mineralocorticoid excess syndrome was excluded based on a normal urine cortisol (F)/cortisone (E) ratio (F/E 0.4, normal range 0.1-0.7). Primary glucocorticoid resistance, 11b-hydroxylase deficiency, and 17a-hydroxylase deficiency were excluded based on both clinical phenotype and normal values of adrenocorticotropic hormone (ACTH), plasma cortisol, 17-OHprogesterone, follicle stimulating hormone (FSH) and lutenizing hormone (LH). Treatment with amiloride 5 mg/day without potassium supplements promptly normalized both BP and serum K þ concentration within 2 weeks, whereas both PRA and plasma aldosterone were still low after 20 weeks. Suppression of both plasma aldosterone concentration and urinary aldosterone excretion persisted for 4 weeks following the increase of the amiloride dose to 7.5 mg/day (Table 1) .
Ambulatory BP monitoring was performed twice: before starting any pharmacological treatment (when the patient was 16 years old) and 6 months following the initiation of amiloride treatment. The mean 24-h BP levels decreased from 158/86 to 126/72 mmHg, daytime levels from 156/89 to 128/73 mmHg, and nighttime levels from 161/77 to 115/65 mmHg. The proband's family was of Sicilian-Calabrian origin (southern Italy), with the exception of the paternal grandmother's father who was of Piedmontese origin (northern Italy). The paternal line was strongly suspected of carrying the mutation (Fig. 1) . The proband's father was severely hypertensive at age 18 and died of a heroin overdose at age 20. The paternal grandmother was hypertensive at age 19 and died of stroke at age 42.
Subjects
Genetic analysis was performed in the proband, the proband's mother, and the proband's paternal great-aunt; other relatives of the proband were not available for examination. DNA obtained from 50 healthy blood donors and 50 subjects with essential hypertension was also analyzed. This study was approved by the Ethical Committee of Reggio Emilia Hospital, and all participating subjects gave their informed consent. Biochemical measurements Quantitative analysis of urinary free cortisol and free cortisone was performed using a solid-phase extraction column and high-performance liquid chromatography (HPLC) with ultraviolet (UV) detection [27] . Other biochemical and hormonal measurements were performed using standard methods.
DNA analysis
Genomic DNA was extracted using a rapid extraction kit (Puregene extraction kit D-40K; Gentra Systems, Minneapolis, Minnesota, USA) from 300 ml of whole blood by standard methods. PCR amplified two DNA fragments corresponding to coding sequences of the C-terminal exons of the SCNN1B gene (from codon 515 to 640) and SCNN1G gene (from codon 523 to 648). In particular, the SCNN1B amplicon (fragment size 463 bp) spans from 30 bp of the final part of introns 12-13 to exon 13, comprising 52 bp of 3 0 UTR; the SCNN1G amplicon (fragment size 432 bp) includes 29 bp of introns 12-13 and 403 bp of exon13 (the entire coding region plus 22 bp of 3 0 UTR region). PCR primers for SCNN1B (sense 5 0 -GAGCT CACCCCAGCTCCCTG-3 0 , antisense 5 0 -CAGTCTTG GCTGCTCAGTGAG-3 0 ) and SCNN1G (sense 5 0 -TT GATGGTGTGGCTTGGCCTG-3 0 , antisense 5 0 -GAT CTGTCTTCTCAAACCCTGC-3 0 ) were designed using Web Primer (http://seq.yeastgenome.org/cgi-bin/webprimer). The PCR reaction was conducted in 50 ml volume containing 100 mmol/l of each dNTP, 20 pmol each primer, 1 unit Taq polymerase and 100 ng genomic DNA. The PCRs were carried out in a MasterCycler Gradient thermal cycler (Eppendorf AG, Hamburg, Germany). Amplification profile was as follows: initial denaturation 958C for 2 min, 35 cycles of 948C for 30 s, 668C for 30 s, 728C for 30 s, and final extension at 728C for 3 min.
Forty microliter aliquots of the PCR products were purified using the AmPure PCR Purification System (Agencourt, Beverly, Massachusetts, USA) and subjected to dye terminator cycle sequencing (DTCS) with the DTCS kit (Beckman Coulter, Fullerton, California, USA) in 20 ml reaction volumes with 20 ng of DNA and 3.2 pmol of one of the PCR primers. The temperature programming for sequencing involved 30 cycles with steps of 968C for 20 s, 508C for 20 s, and 608C for 3 min, followed by maintainence at 48C. Sequencing reaction products were precipitated using ethanol, dried, and finally resuspended in 40 ml of deionized formamide sample loading solution prior to separation by capillary electrophoresis with an 8-capillary-array CEQ2000XL DNA sequencer (Beckman Coulter). The sequencing reaction was repeated twice using two amplification products to confirm the test.
The direct sequencing of the final sequence of the SCNN1B, performed in the patient, in the patient's mother, and in the patient's great-aunt, identified only in the proband a mutation at codon 617. Within the amplicon obtained from the SCNN1B gene, point mutation C1850T creates a BsrBI restriction site (CCGCTC); thus, this enzyme can reveal the presence of a T or C nucleotide at position 1850 of the SCNN1B transcript corresponding to the second base of codon 617 of reference sequence NP_000327 (NCBI and SwissProt). The PCR product of 463 bp was cleaved into two fragments of 336 and 127 bp only if it contained the mutation at codon 617. Therefore, after sequence analysis, we also analyzed the amplicons obtained from the proband, proband's mother, proband's great-aunt and DNA of both the control individuals and hypertensive subjects by the PCR-restriction fragment length polymorphism (RFLP) method to confirm the presence of point mutation. We performed digestion of an aliquot of 10 ml PCR products using BsrBI restriction endonuclease (New England Biolabs, Beverly, Massachusetts, USA) followed by electrophoresis in a 2% agarose gel stained with ethidium bromide (0.5 mg/ml). Finally, the gel was visualized under UV light to evaluate the digested PCR products.
Furthermore, the CYP11B1/CYP11B2 chimeric gene causing glucocorticoid-remediable aldosteronism was excluded in the proband by a long-PCR test [28] .
Functional expression of the bP617L epithelial sodium channel
Preparation of human b-epithelial sodium channel mutant
The QuickChange site directed mutagenesis kit (Stratagene, La Jolla, California, USA) was used with the following primers: 5 0 -CCCAGGCACCCCGCTCCCCA ACTATGACTC-3 0 and 5 0 -GAGTCATAGTTGGGGA GCGGGGTGCCTGGG-3 0 .
cRNA synthesis pSD5 plasmids encoding human a, b wild-type or P617L mutant, and gENaC were linearized and transcribed with SP6 RNA polymerase (Promega Corporation, Madison, Wisconsin, USA) as described previously [29, 30] .
Expression in Xenopus oocytes and electrophysiological measurements
Electrophysiological measurements were carried out as described previously [29] . Briefly, stage V and VI oocytes of X. laevis were injected with 1 ng of cRNA of each ENaC subunit (a, b wild-type or P617L mutant, and g). After 20-24 h of injection, macroscopic amiloridesensitive Na þ currents, defined as the difference between Na þ currents obtained in the presence and absence of 5 mmol/l amiloride (Sigma-Aldrich, St. Louis, Missouri, USA) in the bath, were recorded using the twoelectrode voltage clamp technique.
For current measurements, the oocytes were voltageclamped at 100 mV. The bath solution was a standard oocyte Ringer solution containing 95 mM Na þ activity (85 mmol/l NaCl, 1mmol/l KCl, 2.4 mmol/l NaHCO 3 , 0.4 mmol/l CaCl 2 , 0.3 mmol/l Ca(NO 3 ) 2 , 0.8 mmol/l MgSO 4 , 10 mmol/l HEPES/NaOH, pH 7.2). Oocytes were initially placed in a bath solution containing amiloride to prevent changes in [Na] i , and the current was measured after amiloride washout. Currents were recorded with a TEV-200 amplifier (Dagan Corp., Minneapolis, Minnesota, USA). For each condition, a total of 19-20 oocytes isolated from four different animals was analyzed.
Statistical analysis
The difference in the amiloride-sensitive I Na current between wild-type and b P617L mutant ENaC expressed in Xenopus oocytes was analyzed using the unpaired t-test. A 2-sided P value less than 0.05 was considered statistically significant.
Results
Genetic analysis
A novel heterozygous C to T missense mutation at codon 617 in exon 13 of SCNN1B was detected (CCC to CTC) in the proband, but was not found in the following individuals: his mother, his great-aunt, normal controls, and hypertensive subjects. This mutation is predicted to substitute leucine for the second proline in the PPP Â Y motif of the b subunit (Fig. 2) . Restriction enzyme digestion analysis was consistent with the sequencing analysis (Fig. 3) . No variant of gENaC was detected.
Functional expression of the bP617L epithelial sodium channel To determine the functional role of the bP617L mutant, we expressed abP617Lg or wild-type ENaC in Xenopus oocytes and monitored ENaC activity by measuring amiloride-sensitive Na þ currents by the two-electrode voltage-clamp technique. We found that the expression of the ENaC mutant caused a three-fold increase in the amiloride-sensitive Na þ current compared with wildtype channels (Fig. 4) .
Discussion
We report a novel mutation causing Liddle's syndrome in a young patient with early onset of hypertension. The clinical diagnosis of Liddle's syndrome rested on vertical transmission of early onset hypertension, which suggests dominant autosomal inheritance, pseudohyperaldosteronism, and response to ENaC inhibitors, but not to mineralocorticoid receptor antagonists.
Moreover, ambulatory BP recording before treatment showed a loss of the normal nocturnal fall in BP, as well as an absolute increase in BP levels. After amiloride Identification of the mutation by direct sequencing of exon 13 of the SCNNB1 gene. The sequence extending from codon 615 to codon 618 is shown. Both C and T signals were observed in the second base of codon 617 of the SCNN1B gene in the proband instead of a single C signal observed in the patient's mother, patient's great-aunt and normal subjects. This indicates a C to T mutation in one allele with the other remaining intact. Transition from C to T in the second base of codon 617 predicts a missense mutation of proline 617 to leucine (P617L).
treatment, we observed a normalization of BP levels associated with appearance of the physiological BP nocturnal fall. This finding is reminiscent of the nondipping pattern observed in primary aldosteronism [31] , even if the circadian rhythm of BP in this condition is still debated. As the absence of the BP nocturnal fall may be an independent cardiovascular risk factor [32, 33] , it might partly account for the increased risk of both target organ damage and premature stroke reported in several patients with Liddle's syndrome, provided that the loss of nocturnal BP fall is confirmed in other Liddle's syndrome patients.
Finally, both plasma renin activity and plasma aldosterone levels remained low after 6 months of amiloride treatment, despite the prompt normalization of BP and serum K þ . Indeed, chronic volume expansion caused by constitutive activation of ENaC might lead to a sort of 'disuse atrophy' of juxtaglomerular cells and glomerulosa cells [1] . Alternatively, the daily dose of amiloride in our patient could have been too low for a complete recovery of the renin-angiotensin-aldosterone axis.
Genetic analysis of patients with Liddle's syndrome has so far identified 13 mutations in bENaC [7] [8] [9] [10] [11] [12] [13] [14] 16, [18] [19] [20] [21] [22] [23] [24] [25] [26] and four in gENaC [14] [15] [16] [17] . These are either gross deletion, nonsense, or frameshift mutations in the b or g subunits that abrogate the PY-motif [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] , as well as missense mutations that change the PY-motif in the Cterminal end of the b subunit of ENaC [16, [18] [19] [20] [21] [22] [23] [24] [25] [26] . One isolated case is gENaC Asn530Ser, which is located in the extracellular loop of the g subunit and does not affect the PY-motif [14] . The mutation detected in the present study, P617L, is within the PY-motif of bENaC (Table  2 ). This motif, together with the PY-motifs in a and gENaC, is the recognition site for the ubiquitin-protein ligase Nedd4-2 that interacts through its WW domains with these motifs, thereby ubiquitylating (i.e. modifying with ubiquitin polypeptides) the channel and targeting it for internalization and degradation [34] [35] [36] . Mutations causing deletion or alteration of the PY-motif prevent Nedd4-2 binding to ENaC and, as a consequence, internalization/degradation of ENaCs fails to occur, resulting in increased density of ENaC at the apical membrane of the aldosterone-sensitive distal nephron [34, [37] [38] [39] [40] . In addition to an increase in channel number at the cell surface, inhibition of ENaC ubiquitylation increases channel open probability, possibly by stimulating channel activating proteases, which remove inhibitory peptides from the extracellular loop of a and g subunits [41] . The solution structure of the complex with one of the WW domains of Nedd4 and the PY-motifs of bENaC has been analyzed [42] . Thereby, it was found that the PY-motif adopts a polyproline type II (PPII) helix that is formed by Pro616 to Asn619, and the same residues, as well as Tyr620 and Leu623, are involved in the binding. Hence, P617 appears to play a crucial role in the formation of the PPII helix and the interaction with the WW domain, and mutation to Leu is expected to interrupt the helix structure and consequently the binding to the WW domain [42] . Our data confirm the findings of another previously identified mutation of the same residue (P617S) [21] , corroborating the crucial role of P617 in the regulation of ENaC. Similarly, functional expression of the P617L mutation in the X. laevis oocyte system (Fig. 4) demonstrates its A novel mutation causing Liddle's syndrome Rossi et al. 925 Restriction digestion analysis of the PCR-amplified 463 bp sequence of SCNN1B. The mutation of codon 617 (CCC to CTC) creates a recognition site for BsrBI. The PCR product was cleaved into two fragments of 336 and 127 bp only in the mutant allele. Functional expression of the bP617L epithelial sodium channel (ENaC). Amiloride-sensitive Na þ current (I Na ) is increased in Xenopus laevis oocytes expressing mutant epithelial sodium channels (abP617Lg) compared with those expressing wild-type channels. The mean current (AESEM) of a total of 19-20 oocytes isolated from four different animals is displayed. Values are significantly different between wild-type and mutant ENaC (P < 0.01). wt, wild type.
gain-of-function properties. Such increase has also been shown with other Liddle's mutations mentioned above [3, 8, 14, 15, 18, 19, 21, 23] .
Early onset of hypertension (before 20 years of age) in the proband's father and paternal grandmother, together with the absence of the mutation in the proband's mother, suggests that the proband inherited this condition from the paternal lineage, through autosomal dominant transmission. Genomic DNA from the proband's father and paternal grandmother could, however, not be obtained as both had already died. Moreover, the paternal great-aunt did not display the mutation. Therefore, a de-novo mutation cannot be ruled out. In fact, a few de-novo mutations have been previously detected in patients with Liddle's syndrome [13, 16, 18, 20] . To our knowledge, this is the first report of Liddle's syndrome in the Italian population, confirmed by genetic and functional analysis, with the identification of a gain-of-function mutation not previously reported. Although Liddle's syndrome is considered a very rare condition, it is probably underdiagnosed. Indeed, neither severe hypertension nor hypokalemia are invariable findings in Liddle's syndrome [2, 8, 19] . Moreover, the absence of a family history of Liddle's syndrome does not exclude the diagnosis in subjects with low-renin, lowaldosterone hypertension, as de-novo mutations may be responsible for sporadic cases. Furthermore, functional tests (response to mineralocorticoid receptor inhibitors or dexamethasone vs. epithelial sodium channel inhibitors, aldosterone response to cosyntropin) are time consuming and potentially misleading, as their diagnostic accuracy has not been formally established. This underscores the difficulty in establishing or excluding the diagnosis of Liddle's syndrome on clinical grounds. On the contrary, a reliable diagnosis is strongly desirable, considering both the excellent response of Liddle's syndrome to ENaC inhibitors and the risk of cardiovascular, cerebrovascular, and renal complications associated with incompletely corrected Liddle's syndrome.
Genetic screening may be a timesaving and crucial tool for Liddle's syndrome detection in patients with lowrenin, low-aldosterone hypertension and with hypokalemic alkalosis. As the mutations causing Liddle'syndrome are clustered in very short segments of the C-termini of either the b or g subunit, screening by direct sequence DNA analysis is simple and feasible. Furthermore, if the mutation creates a new recognition site for a restriction enzyme, RFLP allows one to obtain a rapid confirming or excluding diagnosis in the other members of the family. 
